- Home
- RFL vs XGN Comparison
RFL vs XGN Comparison
Compare RFL & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFL
- XGN
- Stock Information
- Founded
- RFL 2017
- XGN 2002
- Country
- RFL United States
- XGN United States
- Employees
- RFL N/A
- XGN N/A
- Industry
- RFL Real Estate
- XGN Medical Specialities
- Sector
- RFL Finance
- XGN Health Care
- Exchange
- RFL Nasdaq
- XGN Nasdaq
- Market Cap
- RFL 48.4M
- XGN 49.4M
- IPO Year
- RFL N/A
- XGN 2019
- Fundamental
- Price
- RFL $2.40
- XGN $2.65
- Analyst Decision
- RFL
- XGN Buy
- Analyst Count
- RFL 0
- XGN 1
- Target Price
- RFL N/A
- XGN $7.00
- AVG Volume (30 Days)
- RFL 65.0K
- XGN 24.1K
- Earning Date
- RFL 12-12-2024
- XGN 11-11-2024
- Dividend Yield
- RFL N/A
- XGN N/A
- EPS Growth
- RFL N/A
- XGN N/A
- EPS
- RFL N/A
- XGN N/A
- Revenue
- RFL $540,000.00
- XGN $56,660,000.00
- Revenue This Year
- RFL N/A
- XGN $9.98
- Revenue Next Year
- RFL N/A
- XGN $13.63
- P/E Ratio
- RFL N/A
- XGN N/A
- Revenue Growth
- RFL 92.86
- XGN 7.05
- 52 Week Low
- RFL $1.29
- XGN $1.30
- 52 Week High
- RFL $2.44
- XGN $3.71
- Technical
- Relative Strength Index (RSI)
- RFL 87.25
- XGN 39.30
- Support Level
- RFL $2.00
- XGN $2.64
- Resistance Level
- RFL $1.94
- XGN $3.03
- Average True Range (ATR)
- RFL 0.10
- XGN 0.17
- MACD
- RFL 0.03
- XGN -0.05
- Stochastic Oscillator
- RFL 94.85
- XGN 1.67
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.